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Abstract: Calcium (Ca2+) is perhaps the most versatile signaling molecule in cells. Ca2+ regulates a
large number of key events in cells, ranging from gene transcription, motility, and contraction, to
energy production and channel gating. To accomplish all these different functions, a multitude of
channels, pumps, and transporters are necessary. A group of channels participating in these processes
is the transient receptor potential (TRP) family of cation channels. These channels are divided into
29 subfamilies, and are differentially expressed in man, rodents, worms, and flies. One of these
subfamilies is the transient receptor potential canonical (TRPC) family of channels. This ion channel
family comprises of seven isoforms, labeled TRPC1–7. In man, six functional forms are expressed
(TRPC1, TRPC3–7), whereas TRPC2 is a pseudogene; thus, not functionally expressed. In this review,
we will describe the importance of the TRPC channels and their interacting molecular partners in the
etiology of cancer, particularly in regard to regulating migration and invasion.
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1. Introduction
Increasing evidence during the past decade indicates that different ion channels are expressed
in several cancers in humans, and regulate a multitude of cellular processes, including migration,
invasion and proliferation [1–3]. Hence, ion channels have emerged as potential targets for cancer
therapy. Of the channels considered important for cancer progression, special interest has been given
to Ca2+ channels, as Ca2+ signaling is of crucial importance in the regulation of many cellular processes.
Different Ca2+ channels gate Ca2+ ions into the cell, where after Ca2+ bind to Ca2+ binding proteins
and activate downstream signaling pathways, resulting in specific cellular responses. These include
motility and contraction, energy production, and gene transcription. To make this versatility possible,
several different, pumps, transporters, and channels are necessary [4–6].
In many cancer forms, Ca2+ signaling plays an essential role in cell migration, invasion, and
proliferation through transient receptor potential canonical (TRPC) channels, a subfamily of the
transient receptor potential (TRP) superfamily of Ca2+ ion channels. The TRPC subfamily comprises
six members in humans, TRPC1 and TRPC3–7. Many of these channels are ubiquitously expressed
in human tissues and modulate a multitude of cellular responses [7–12]. Some of these channels
function both as receptor operated Ca2+ entry (ROCE) and as store operated Ca2+ entry (SOCE)
channels [1,13,14]. In the present review, we want to highlight the importance of different TRPC
channels in the migration and invasion of cancer cells. For a recent, comprehensive overview of the
importance of different ion channels, and not exclusively TRPC channels, see [2,3].
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2. Calcium Signaling
Ca2+ is a ubiquitous intracellular second messenger and activates numerous cellular processes,
including fluid secretion, muscle contraction, exocytosis, gene transcription, fertilization, cell
differentiation, proliferation and migration [4,15,16].
Ca2+ entry into the cells can be evoked by depolarization of the plasma membrane and the
activation of voltage-operated calcium channels (VOCs). These channels are mainly found in excitable
cells, such as neurons and muscle cells. An increase in calcium entry can also be obtained in response to
an agonist stimulus that, through G protein coupled receptors (GPCR), activates membrane-associated
phospholipase C (PLC), and generates two important second messengers, inositol 1,4,5-triphosphate
(IP3) and diacylglycerol (DAG). DAG has been shown to activate receptor-operated calcium entry
(ROCE) by activation of TRPC channels, which enables Ca2+ influx into the cells. The IP3 diffuses into
the cytoplasm and activates IP3 receptors on the endoplasmic reticulum (ER), resulting in the release
of Ca2+ from the ER stores [4,17–20]. The extracellular Ca2+ concentration, which usually is 2–3 mM,
is huge as compared to the intracellular free Ca2+ concentration at resting state. The resting level of
free Ca2+ in the cytoplasm is maintained at low concentration, about 100 nM. The steep concentration
gradient facilitates rapid Ca2+ entry into the cells. Cells maintain the low level of cytosolic Ca2+ by
strict regulation of Ca2+ channels, pumps, and Ca2+ binding proteins (Figure 1). The Ca2+ signals
in cells are normally in the form of rapid transients in the free cytosolic Ca2+ concentrations. The
abnormality or impairment of the cytosolic Ca2+ transients may induce severe diseases [6,20,21].
Figure 1. Mechanisms of Ca2+ signaling. Upon activation of a G-protein coupled receptor (GPCR) by
an agonist, phospholipase C (PLC) is activated, which generates two second messengers; diacylglycerol
(DAG) and inositol 1,4,5-triphosphate (IP3). DAG is capable of activating TRPC channels in the plasma
membrane and Ca2+ influx is triggered. IP3 diffuses through the cytoplasm and binds to IP3 receptors
on the endoplasmic reticulum (ER) membranes. This binding enables ER depletion, resulting in a rapid
Ca2+ transient. The depletion of ER is sensed by stromal interaction protein 1 (STIM1) proteins which
act as sensors. STIM1 makes a complex with Orai1 channels in the plasma membrane and induces
store operated Ca2+ entry through Orai1. Voltage-operated calcium channels open in response to a
depolarization of the plasma membrane in excitable neural and muscle cells. Ca2+ in the cytoplasm
activates ryanodine receptors and Ca2+ is released from the endoplasmic reticulum (ER). To avoid a
Ca2+ flood in the cytoplasm, the pumps sarcoplasmic-endoplasmic reticulum Ca2+ATPase (SERCA)
and plasma membrane Ca2+ATPase (PMCA), and the sodium calcium exchangers (NCX), are activated
which export Ca2+ out of the cell or into the ER. The secretory pathway Ca2+ ATPase (SPCA) transports
Ca2+ ions into the Golgi apparatus.
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The increase in the cytoplasmic Ca2+ levels enables Ca2+ binding proteins such as EF-hand
proteins, annexins, and C2-domain proteins to become active and to regulate several cellular processes,
such as muscle contraction, exocytosis, metabolism, gene transcription, fertilization, proliferation, and
hypertrophy. To avoid too much of Ca2+ in the cytoplasm, the levels of Ca2+ in the cytoplasm are
strictly regulated. However, the Ca2+ signals may have a duration ranging from microseconds to
hours, depending upon the cell type and the specific function of the signal. Persistently elevated Ca2+
levels in the cytoplasm can lead to apoptosis and cell death. Moreover, irregular, e.g., high, or low
amplitude Ca2+ signals have been associated with diseases [6,21].
3. Transient Receptor Potential (TRP) Channels
In the fly, Drosophila melanogaster, a mutant that caused temporary blindness in bright light
stimulus was detected, and later it was found that this mutation encodes a cation transient receptor
potential (TRP) channel [22–24]. The TRP channel-superfamily is the largest family of cation channels
and is comprised of 17 different channels in worms, 13 in flies, 28 in mice, and 27 in humans, as shown
in Table 1.
Table 1. Expression of transient receptor potential (TRP) channels in worms, flies, mice, and humans.
TRPC 3 3 7 6
TRPV 5 2 6 6
TRPM 4 1 8 8
TRPA 2 4 1 1
TRPML 1 1 3 3
TRPP 1 1 3 3
TRPN 1 1 0 0
Total 17 13 28 27
The expression and function of TRP channels is diverse throughout the animal kingdom, including
worms, flies, mice, and humans. There are seven subfamilies of TRP channels based on amino acid
sequence homology, and include TRPC (canonical), TRPV (Vanilloid), TRPML (Mucolipin), TRPP
(Polycystin), TRPM (Melastatin), TRPA (Ankyrin), and TRPN (no mechanoreceptor potential C), as
shown in Figure 2.
TRP channels are selective to cations and some subtypes are highly selective for Ca2+ and Mg2+.
The channels are ubiquitously expressed in human tissues. Many TRP channels have been indicated to
participate in a multitude of physiological processes including perception of heat, touch, pain, odor
and smell, cellular regulation of osmolarity, fluid secretion, inflammation, cell adhesion, proliferation,
cell differentiation, migration, and apoptosis [15,25–34]. In addition to the physiological importance,
TRP channels have been found to regulate many diseases, including cancer [35–39].
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Figure 2. The human phylogenetic tree of the TRP channel superfamily. TRPC (canonical), TRPV
(Vanilloid), TRPML (Mucolipin), TRPP (Polycystin), TRPM (Melastatin), TRPA (Ankyrin), and TRPN
(NOMPC). TRPC2 is a pseudogene in human. TRPN is expressed in fish.
3.1. TRPC Channels
The transient receptor potential canonical (TRPC) subfamily consists of seven members (TRPC1-7).
In humans, all isoforms are expressed except TRPC2, which is a pseudogene. TRPCs are non-selective
cation channels, with a preference for Ca2+ over Na+ and K+ ions. The structure of the TRPC channels
consists of six transmembrane segments (S1–S6) connected through loops, and the amino (N) and the
carboxyl (C) terminals are located in the cytoplasm. The length and amino acid sequence of the C or N
terminals varies. The loop region between segments 5 and 6 makes the pore, which conducts ions
as shown in Figure 3. The N-terminus has a coiled-coil domain and four ankyrin domains, which
facilitates protein interactions and has been shown to be involved in the regulation of TRPC channel
function by tetramerization of TRPC subunits [40]. The C-terminus has a TRP domain, which is the
site for other TRP channel isoforms to bind and form channel complexes, a coiled-coil domain, and a
calmodulin and IP3R binding site, which regulates the activation and inhibition of the channel [41].
TRPCs regulate several Ca2+ dependent cellular processes. TRPC1 can co-assemble with all other TRPC
isoforms (TRPC3-7). The TRPC1/TRPC3 complex enhances SOCE, and regulates the differentiation of
e.g., H19-7 hippocampal neuronal cells [42]. TRPC channels participate in both ROCE as well as SOCE
together with Orai1 and STIM1 proteins.
Figure 3. TRPC channel transmembrane structure and the domain organization of the subunits.
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3.1.1. TRPC1
TRPC1 channels are ubiquitously expressed in human tissues and participate in carrying out
many cellular processes, including cell migration and proliferation [11,13,14,43]. TRPC1 is the first
mammalian TRPC channel identified and cloned [44]. TRPC1 has been established as a potent molecular
component of SOCE in several distinct cell types [19,45–47]. In addition, TRPC1 has been shown to
function as a ROCE channel in several cell lines [48,49]. TRPC1 can make complexes with all other
TRPC channels. In HSY cells, TRPC1 forms a complex with TRPC3. In human embryonic kidney
(HEK-293) cells, TRPC1 forms a heterotrimeric complex with both TRPC3 and TRPC7. In mesangial
cells, TRPC1 forms a complex with TRPC4 and in neuronal cells TRPC1 has been shown in complex
with TRPC5 [11,50–53]. TRPC1 channels also interact with the Ca2+ signaling proteins Gq/11, PLC,
calmodulin, IP3 receptors (IP3R), PMCA, SERCA, and STIM1 to regulate cellular processes. STIM1
and the TRPC1-TRPC4 complex are essential for store refilling and differentiation in myotubes [54].
3.1.2. TRPC2
TRPC2 is a pseudogene and does not form a functional channel in humans [44,55]. Relatively
little is known about this channel’s physiology and pathology. However, in other mammals, TRPC2
forms a functional channel in distinct tissues, such as the vomeronasal organ (VNO), testis, spleen
and liver [55,56]. The importance of TRPC2 in the vomeronasal organ has obtained much interest in
regard to pheromone detection, see reviews [57,58]. TRPC2 has been shown to interact with Homer 1,
calmodulin, Gq/11, IP3R, and receptor transporting protein 1 (RTP1) [59–61]. We detected TRPC2 in
the rat thyroid FRTL-5 cell line. Knockdown of TRPC2, or expression of a dominant negative form
of TRPC2 in these cells resulted in a significant decrease in proliferation, migration, adhesion and
invasion [62]. In addition, TRPC2 has the ability to mediate both ROCE and SOCE in FRTL-5 cells [63].
3.1.3. TRPC3
TRPC3 channels are expressed in the human brain, kidney, skeletal muscle, mammary, ovary
and cardiovascular tissues [14]. TRPC3 interacts and forms heterodimers with TRPC1, 4, 5, 6, and 7.
Despite a considerable homology of the amino acid sequence between TRPC3, TRPC6, and TRPC7,
these channels regulate many different functions in humans [64,65]. TRPC3 also interacts with the
Orai1 calcium channel [66,67]. TRPC3, either in complex with TRPC1, or in complex with both TRPC1
and TRPC7, forms a SOCE channel. TRPC3 interacts with several signaling proteins in response to
receptor-evoked Ca2+ mobilization, including PLCβ, Gq/11, and IP3R. TRPC3 has been reported to be
directly activated by DAG [68].
3.1.4. TRPC4
TRPC4 shares a 65% homology in the amino acid sequence with TRPC5 [19,45]. Mostly, TRPC4
channels form SOCE channels, but in some cell types, they form store-independent channels as well. It
can make heteromeric channels with TRPC6. STIM1 binds with TRPC4 and regulates its function as a
SOCE channel [69]. Furthermore, TRPC4 has been studied extensively in regard to endothelial cell
function and has been shown to regulate proliferation of these cells [14,70].
3.1.5. TRPC5
TRPC5 is highly expressed in neuronal cells and regulates their function. In HEK-293 cells, TRPC5
is a non-selective channel and functions as a ROCE channel but not as a SOCE channel [71]. Recently,
it has been shown that TRPC5 is activated in response to mechanical stress, and this increase in the
activity of the channel is dependent on actin filaments [72]. TRPC5-TRPC1 complexes are found in
neurons, vascular endothelial cells, and smooth muscle cells. In vascular smooth muscle (VSM) cells,
TRPC5 has been suggested to act as SOCE channel by forming complexes with TRPC1, TRPC6, and
TRPC7 [73].
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3.1.6. TRPC6
TRPC6 is expressed in pulmonary and vascular smooth muscle cells. These channels are directly
activated by DAG and do regulate ROCE [74]. However, activation of TRPC6 due to Ca2+ release
from the ER is mediated by Orai1 and TRPC4 [75]. TRPC6 has been shown to make a complex with
TRPC3 in neuronal cells and prostate cancer epithelial cells. In astrocytes, sphingosine 1-phosphate
(S1P)-evoked secretion of the C-X-C motif chemokine ligand 1 (CXCL1) is mediated through activation
of TRPC6 and the mitogen-activated protein kinase (MAPK) signaling pathway [76]. Furthermore,
TRPC6 is important in transforming growth factor β1 (TGFβ1) signaling in vascular smooth muscles.
TGFβ1 induces stress fiber formation in these cells via upregulation of TRPC6 [77]. The interplay of
leukocytes with platelet/endothelial cell adhesion molecule-1 (PECAM) result in activation of TRPC6
which modulates subsequent leukocyte transendothelial migration (TEM) [78].
3.1.7. TRPC7
In humans, TRPC7 is widely expressed in many tissues including the brain, skin, cartilage,
pituitary gland, intestine, kidney, and prostate [14]. TRPC7, a non-selective cation channel, is the
seventh identified member of mammalian TRPC family. It was isolated through molecular cloning of
the mouse fetal brain and caudate nucleus cDNA libraries [79,80]. The role of TRPC7 in the regulation
of normal cell physiology and pathology is still indefinable. TRPC7 is activated by Gq-coupled protein
receptors and the PLC pathway and is directly activated by DAG. In some cell types, TRPC7s are
constitutively active proteins and may function as SOCE channels by forming a TRPC1-TRPC3-TRPC7
complex. However, in HEK-293 cells, a TRPC3 and TRPC7 complex is activated by DAG and functions
as ROCE channels [81]. Furthermore, cGMP-dependent protein kinase 1α, calmodulin, IP3R, and
phosphatidylinositol 4,5,-bisphosphate (PIP2) have all been reported to regulate the function of
TRPC7 [82]. In addition, activation of TRPC7 potently induces myocardial apoptosis [83].
4. TRPC Channels as Regulators of Migration and Invasion
4.1. TRPC Channels, Migration and Invasion
Several TRPC channels are involved in regulating migration and invasion, and all are involved
in enhancing proliferation of cancer cells [84–86]. TRPC1 channels are essential for the polarity and
direction of migrating cells both in vitro and in vivo [49,51,52]. The directionality of migrating cells, as
shown using renal transformed epithelial cells, was dependent on TRPC1 [87]. In aggressive glioma
cells, TRPC1 regulates epidermal growth factor (EGF)-evoked migration [88]. In addition, TRPC1 has
been shown to localize to lipid rafts at the leading edge of migrating cells. TRPC1 mediated Ca2+
entry has been shown to activate the MAPK and phosphoinositide 3-kinase/Akt (PI3K/Akt) signaling
pathways, calpains, hypoxia-induced factor 1α (HIF1α) and several matrix-metalloproteinases (MMPs).
Thus, TRPC1 has emerged as an important player involved both in normal and cancer cell function [49].
Furthermore, TRPC1 may be in complex with the small conductance Ca2+ activated potassium channel
(SK3) and Orai1 to enhance SOCE-dependent colon cancer migration [89]. In skeletal myoblast
migration, TRPC1 is of importance to evoke Ca2+ -mediated activation of calpains [11]. Silencing
TRPC1 by siRNA inhibited invasion of CNE2 nasopharyngeal tumor cells [90].
We have shown that TRPC1 is a potent regulator of both migration and invasion in follicular thyroid
cancer ML-1 cells [91]. The mechanisms involved appear to depend on the at least MAPK/ERK1/2,
MMP2 and-9, and HIF1α. However, so far, no studies regarding TRPC1 in thyroid cancer have been
performed. The importance of TRPC channels in normal thyroid cells has, to the best of our knowledge,
not been investigated.
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The importance of TRPC2 as a regulator of invasion and migration has not been extensively
studied. In thyroid cells, Ca2+ has many important functions [63,92], and we have shown that, in
normal rat thyroid FRTL-5 cells, TRPC2 potently regulates migration, invasion, and adhesion [62]. Rac,
calpain and MMP2 seem to be of importance in TRPC2-regulated migration. Considering that thyroid
cells migrate during embryogenesis [93], our data suggest that TRPC2 might have a role in this event
in rodents. Although TRPC2 knock-out mice appear normal (except for their behavioral changes, see
e.g., [94]), it would also be of interest to investigate the thyroid status in these mice.
The importance of TRPC3 as a regulator of migration and invasion has been studied in several
different tumor cells. In human ovarian cancer, the expression of TRPC3 was increased, and injection
of TRPC3-knock down SKOV3 cells decreased tumor formation in nude mice [95]. In pancreatic
stellar cells, activation of KCa3.1 results in activation of TRPC3-evoked Ca2+ entry, calpain activity,
and concomitant cell migration [96]. TRPC3 also enhanced melanoma cell migration and tumor
formation both in vitro and in vivo [97]. Furthermore, TRPC3, together with mGluR5, has been shown
to enhance motility in embryonic neuronal cells as a result of endocannabinoid stimulation [98]. It has
also been shown that the invasion of bladder cancer cells is dependent on both TRPC3 and TRPC6.
Interestingly, in these cells the expressional level of these channels is under the control of the histone
variant macroH2A [99].
Not much is known regarding the importance of TRPC4 or TRPC5 in enhancing migration and
invasion of cancer cells, although at least TRPC4 seems to have a role in proliferation and tumor
formation [100]. Furthermore, TRPC4 seems to enhance invasion of certain forms of medulloblastoma
cells. In these cells, the expression of TRPC4 appears to be regulated by the proton sensing G-protein
coupled receptor 1 (OGR1) [101]. Several TRPC isoforms, including TRPC4, have also been suggested
to enhance proliferation of non-small cell lung cancer [102]. The importance of TRPC5 has been shown
in regulating hippocampal neurite length and growth cone morphology, by having an inhibiting role
in neurite extension [103]. Furthermore, in fibroblasts and kidney podocytes, TRPC5 is in complex
with Rac1, enhancing cell motility, whereas TRPC6-evoked Ca2+ entry enhances RhoA activity; thus,
inhibiting cell motility [104]. Interestingly, the plant derived compound Englerin A induces cytotoxicity
in some cancer cell lines expressing TRPC4 and TRPC5 by enhancing channel activity; thus, increasing
cytosolic Ca2+ and so Na+ concentrations [105,106].
In addition to TRPC1 and TRPC3, the involvement of TRPC6 in cancer cell invasion and migration
has been extensively investigated [3]. In human head and neck squamous cell carcinomas (HNSCC),
TRPC6 was overexpressed, and knock-down of TRPC6 in HNSCC potently attenuated invasion [107].
TRPC6 was also shown to be of significant importance in regulating Notch-driven glioblastoma growth
and invasiveness [108]. In human prostate cancer epithelial (hPCE) cells, active TRPC6 and nuclear
factor of activate T cells (NFAT) promote proliferation via alpha 1-adreniergic receptor signaling [109].
In non-small cell lung cancer A549, TRPC6 was important for invasion [110]. Interestingly, knock-down
of TRPC6 not only attenuated invasion, but also decreased the expression of the adhesion protein
fibronectin and the tight junction protein ZO-1 [110]. Furthermore, TRPC6 was of importance in
regulating breast cancer MDA-MB-231 cell migration [111]. TRPC6 expression has been found
upregulated in breast cancer cell lines, MCF-7 and MDA-MB-231, compared with normal breast
epithelial MCF10A cells. In vitro knockdown of TRPC6 decreased proliferation and migration in these
cancer cells. In addition, TRPC6 has been shown to interact and translocate Orai1 and Orai3 to the
plasma membrane upon ER Ca2+ store depletion [112].
An overview of TRPC channels expressed in tissues and their respective reported function
regarding invasion and migration has been summarized in Table 2.
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Table 2. Effects of TRPC channels on invasion, migration, and proliferation.
Channel Tissue Cell Line Cell function References
TRPC1
Kidney MDCK-F Migration [87]
Brain cancer D54MG Migration [88]
Colon cancer HCT-116 Migration [89]
Skeletal Muscle C2C12 Migration, differentiation [11]
Nasopharyngeal cancer CNE2 Migration, Invasion [90]
Thyroid cancer ML-1 Migration and Invasion [91]
TRPC2 Rat Thyroid FRTL5 Proliferation, adhesion,migration and invasion [62]
TRPC3
Ovarian cancer SKOV3 Migration [95]
Pancreatic stellate cells RLT-PSC Migration [96]
Melanoma C8161 Migration [97]
Neuronal progenitor cell NPCs Migration [98]
Bladder Cancer LD611 Migration and Invasion [99]
TRPC4
Coronary artery HCAECs Proliferation [70]
Ovarian cancer SKOV3 Proliferation [100]
Medulloblastoma DAOY Migration, Invasion [101]
Lung cancer A549 Proliferation [102]
TRPC5
Rat hippocampal neuron E18 Inhibition of neuriteextension [103]
Mouse Kidney Podocytes Promote migration [104]
TRPC6
Mouse Kidney Podocytes Inhibit migration [109]
Head and neck cancer HNSCC Promote Invasion [107]
Brain cancer U373MG Migration, cell growth [108]
Prostate cancer hPCE Proliferation [109]
Lung cancer A549 Proliferation [110]
Breast Cancer MDA-MB-231 Migration [111]
4.2. TRPC Channels and Angiogenesis
The regulation of angiogenesis is a complex event where calcium signaling plays a significant role.
Endothelial cells express several members of the TRP superfamily, many of which have been shown to be
involved in angiogenesis. Knockdown or inhibition of TRPC3 concealed the endothelial tube formation
by attenuation of VEGF-evoked Ca2+ entry and phosphorylation of MAPK [113], and inhibition of
TRPC4 suppressed the VEGF evoked neovascularization in human retina microvascular endothelial
cells (HRMECs) [114]. TRPC3, 4 and 5 have been shown to participate in in vitro tube formation of
the human umbilical vein endothelial cell-derived cell line EA.hy926 [115], and in mice with ischemic
injury, the knockdown of TRPC5 in endothelial cells (ECs) under-hypoxia inhibited sprouting and
tube formation. However, activation of TRPC5 in these cells restored angiogenesis [116]. TRPC6
has been shown to participate in VEGF evoked sprouting and angiogenesis in human microvascular
endothelial cells (HMVEC) [117]. Furthermore, phosphatase and tensin homolog (PTEN) regulates
TRPC6 activation and subsequent promotion of angiogenesis in primary human pulmonary artery
endothelial cells (HPAEs) [118]. As several comprehensive reviews regarding TRP channels and
angiogenesis have recently been published, we recommend the readers to turn to these for further
information [119–121].
5. Conclusions
It seems clear that TRPC channels (and apparently, also, other members of the TRP superfamily),
can have a profound role in the migration and invasion of cancer cells, and thus in the process of
metastasis. Furthermore, as pointed out by a recent review from the Prevarskaya lab, in many of
the common cancer hallmarks, i.e., uncontrolled proliferation, resistance to programmed cell death,
invasion and metastasis, and angiogenesis, ion channels (including TRP channels) have a clear role [3].
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Thus, it seems obvious that different ion channels are considered putative targets for pharmacological
interventions. However, as the TRPC channels often are ubiquitously expressed, it will be a challenge
to find suitable pharmacological tools to block these channels and curtail cancer without severe side
effects. One possibility could be functionalized nanoparticles that specifically target cancer cells,
see e.g., [122,123]. This area of research is proceeding rapidly, and novel approaches are constantly
developed. It will be interesting to see if these will be used to e.g., carry siRNA to target ion channels
in cancer cells, and whether this approach can be used in patients.
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